Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;14(7):1709-1727.
doi: 10.1007/s13555-024-01197-x. Epub 2024 Jun 11.

Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review

Affiliations
Review

Evaluation of the Safety and Effectiveness of Oral Minoxidil in Children: A Systematic Review

Kimberly N Williams et al. Dermatol Ther (Heidelb). 2024 Jul.

Abstract

The minimal adverse-effect profile and positive clinical response of low-dose oral minoxidil (LDOM) have recently caused the drug to gain popularity for the treatment of hair disorders in adults. However, in the pediatric population, hesitancy still surrounds the use of oral minoxidil given the wide profile of potential side effects the drug offers. This review aims to characterize the safety and use of oral minoxidil in children for the treatment of all disorders to equip physicians with ample knowledge when prescribing oral minoxidil in the pediatric population. A total of 41 studies (19 case reports, 10 cohort studies, 7 retrospective chart reviews, and 5 case series) that reported data on 442 pediatric patients for whom oral minoxidil was used for treatment were included. Conditions for which treatment with minoxidil was described were hair disorders (83.9%, 371/442) and hypertension (11.3%, 50/442); accidental usage (4.8%, 21/442) was also noted in the literature and included in this review. This review is broken down by dosage and describes the safety and efficacy of oral minoxidil in pediatric patients aged 0 to 18 years old for the treatment of hair disorders. This review found that LDOM may represent a safe option for the treatment of hair disorders in children. This study also suggests moderate and high doses of oral minoxidil may not be safe for use in children. Additional studies are needed to further understand this drug's efficacy and safety in children.

Keywords: Alopecia; Alopecia treatment; Children; Efficacy; Hair loss; Minoxidil; Oral minoxidil; Pediatric; Safety; Systemic minoxidil.

PubMed Disclaimer

Conflict of interest statement

Dr. Antonella Tosti is a consultant for DS Laboratories, Monat Global, Almirall, Thirty Madison, Eli Lilly, Bristol Myers Squibb, P&G, Pfizer, and Myovant. Dr. Antonella Tosti is an Editorial Board member of Dermatology and Therapy. Dr. Antonella Tosti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kimberly Williams and Chrislene Olukoga have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart of literature search and screening of studies on oral minoxidil use in children

References

    1. Patel P, Nessel TA, Kumar DD. Minoxidil. StatPearls. Treasure Island (FL): StatPearls; 2024. http://www.ncbi.nlm.nih.gov/books/NBK482378/. Accessed 2024 Apr 8.
    1. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84:737–46. 10.1016/j.jaad.2020.06.1009 - DOI - PubMed
    1. Halling SE, Asling-Monemi K, Herthelius M, et al. Minoxidil therapy in children and young adult patients with renal disease and refractory hypertension: value when multidrug regimens have failed to achieve blood pressure control. J Hum Hypertens. 2010;24:552–4. 10.1038/jhh.2010.40 - DOI - PubMed
    1. Moussa A, Bokhari L, Sinclair RD. Systemic minoxidil as maintenance treatment in alopecia areata: a retrospective case series of 24 patients. Clin Exp Dermatol. 2022;47:753–5. 10.1111/ced.15051 - DOI - PubMed
    1. Perper M, Herskovitz I, Tosti A. Aromatase inhibitor-induced hair loss in two adolescents. Pediatr Dermatol. 2020;37:1125–7. 10.1111/pde.14339 - DOI - PubMed

LinkOut - more resources